Life Sciences

Linguistic And Cultural Considerations When Implementing A Global ‘Bring Your Own Device’ (BYOD) Study

As discussions regarding the Bring Your Own Device (BYOD) clinical trial model intensify, it is imperative that the global and multi-lingual ramifications of the model are examined closely. This research, selected for presentation at ISPOR Asia Pacific in Tokyo, discusses the potential benefits of the BYOD approach and examines linguistic and cultural considerations from global eCOA and BYOD projects. Click to read more about the study aims, results, and conclusion.

A Case Study of Successful Collaboration on a Global Immunology and Dermatology Phase II Study

A review of the Clinical Outcome Assessment (COA) Licensing, Translation and Linguistic Validation and eCOA Migration study between Kayentis and RWS Life Sciences.

Getting The Words Right: Device Documentation And Translation In Asia

The medical device sector has seen increasing harmonization of regulations on both a global and regional basis. Nonetheless, market-entry requirements retain a significant degree of localization, particularly in relation to product labeling and documentation. Asia is no exception. For device companies prepared to negotiate the obstacles, though, the potential rewards of a huge and diverse market are considerable.

Aligning Strategies and Deliverables for Global eCOA Translation Submissions to Ethics Committees in Clinical Trials

Have you ever wondered how to best align your strategies and deliverables in clinical trials when delivering eCOA translation submissions to ethics committees? This research, selected for presentation at DIA Global in Boston, June 2018, addresses this question and proposes specific solutions.

An Investigation of Issues in the Translation and Comprehension of Disease Activity in Patient Reported Outcome (PRO) Measures

The RWS Life Sciences Linguistic Validation and Survey Analyst Teams carried out a study investigating the issues in the translation and comprehension of diseases activity in Patient Reported Outcome (PRO) measures. Learn about what the research entailed, the results of the study and concluding thoughts by viewing RWS's research poster.

Variation in Interpretation of Fatigue Across Neuro-QoL – Fatigue – Version 1.0 Translations

The Research team explores the interpretation of fatigue across translations of the Neuro-QoL - Fatigue - V1.0 [1], adapted from PROMIS(R) item bank questions. Because fatigue assessment can measure impact on physical, mental, and social domains, one should consider the variation of interpretations across languages and disease sufferers.